Weight loss medications in Canada – a new frontier or a repeat of past mistakes?

References

• Twells LK Gregory DM Reddigan J Midodzi WK Current and predicted prevalence of obesity in Canada: a trend analysis CMAJ Open 2014 2 1 E18 26
   PubMedGoogle Scholar
• Flegal KM Kit BK Orpana H Graubard BI Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis JAMA 2013 309 1 71 82 23280227
   PubMed Web of Science ®Google Scholar
• Must A Spadano J Coakley EH Field AE Colditz G Dietz WH The disease burden associated with overweight and obesity JAMA 1999 282 16 1523 1529 10546691
   PubMed Web of Science ®Google Scholar
• De Pergola G Silvestris F Obesity as a major risk factor for cancer J Obes 2013 2013 291546 24073332
   PubMedGoogle Scholar
• Dakour Aridi HN Wehbe MR Shamseddine G Alami RS Safadi BY Long-term outcomes of Roux-en-Y gastric bypass conversion of failed laparoscopic gastric band Obes Surg 2017 27 6 1401 1408 28108969
   PubMed Web of Science ®Google Scholar
• Curioni CC Lourenço PM Long-term weight loss after diet and exercise: a systematic review Int J Obes (Lond) 2005 29 10 1168 1174 15925949
   PubMed Web of Science ®Google Scholar
• Fung M Wharton S Macpherson A Kuk JL Receptivity to bariatric surgery in qualified patients J Obes 2016 2016 5372190 27516900
   PubMedGoogle Scholar
• Wharton S Serodio KJ Kuk JL Sivapalan N Craik A Aarts MA Interest, views and perceived barriers to bariatric surgery in patients with morbid obesity Clin Obes 2016 6 2 154 160 26910303
   PubMedGoogle Scholar
• Johns DJ Hartmann-Boyce J Jebb SA Aveyard P Diet or exercise interventions vs combined behavioral weight management programs: a systematic review and meta-analysis of direct comparisons J Acad Nutr Diet 2014 114 10 1557 1568 25257365
   PubMed Web of Science ®Google Scholar
• Miller WC Koceja DM Hamilton EJ A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention Int J Obes 1997 21 10 941 947
   Web of Science ®Google Scholar
• Brownell KD Jeffery RW Improving long-term weight loss: pushing the limits of treatment Behav Ther 1987 18 4 353 374
   Web of Science ®Google Scholar
• Jeffery RW Drewnowski A Epstein LH Long-term maintenance of weight loss: current status Health Psychol 2000 19 1S 5 16 10709944
   PubMed Web of Science ®Google Scholar
• Strohacker K Carpenter KC McFarlin BK Consequences of weight cycling: an increase in disease risk? Int J Exerc Sci 2009 2 3 191 201 25429313
   PubMedGoogle Scholar
• Mayo Clinic Staff Bariatric surgery - Mayo Clinic 2016 Available from: http://www.mayoclinic.org/tests-procedures/bariatric-surgery/basics/why-its-done/prc-20019138 Accessed June 25, 2017
   Google Scholar
• Lau DC Douketis JD Morrison KM Hramiak IM Sharma AM Ur E 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary] CMAJ 2007 176 8 S1 13
   PubMed Web of Science ®Google Scholar
• Hutter MM Schirmer BD Jones DB First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass Ann Surg 2011 254 3 410 422 21865942
   PubMed Web of Science ®Google Scholar
• Rodgers RJ Tschöp MH Wilding JP Anti-obesity drugs: past, present and future Dis Model Mech 2012 5 5 621 626 22915024
   PubMed Web of Science ®Google Scholar
• Dietrich MO Horvath TL Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons Nat Rev Drug Discov 2012 11 9 675 691 22858652
   PubMed Web of Science ®Google Scholar
• Hansen TK Dall R Hosoda H Weight loss increases circulating levels of ghrelin in human obesity Clin Endocrinol (Oxf) 2002 56 2 203 206 11874411
   PubMed Web of Science ®Google Scholar
• Schmidt JB Gregersen NT Pedersen SD Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men Am J Physiol Endocrinol Metab 2014 306 11 E1248 56 24735885
   PubMed Web of Science ®Google Scholar
• Park CW Torquati A Physiology of weight loss surgery Surg Clin North Am 2011 91 6 1149 qq61 vii 22054145
   PubMed Web of Science ®Google Scholar
• Ionut V Bergman RN Mechanisms responsible for excess weight loss after bariatric surgery J Diabetes Sci Technol 2011 5 5 1263 1282 22027328
   PubMedGoogle Scholar
• Arble DM Sandoval DA Seeley RJ Mechanisms underlying weight loss and metabolic improvements in rodent models of bariatric surgery Diabetologia 2015 58 2 211 220 25374275
   PubMed Web of Science ®Google Scholar
• Suzuki K Jayasena CN Bloom SR Obesity and appetite control Exp Diabetes Res 2012 2012 824305 22899902
   PubMedGoogle Scholar
• Roche Xenical Product Monograph 2015 Available from: http://www.rochecanada.com/content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/Mono-graphsandPublicAdvisories/Xenical/Xenical_PM_E.pdf Accessed April 3, 2017
   Google Scholar
• Rucker D Padwal R Li SK Curioni C Lau DC Long term pharmacotherapy for obesity and overweight: updated meta-analysis BMJ 2007 335 7631 1194 1199 18006966
   PubMed Web of Science ®Google Scholar
• Li Z Maglione M Tu W Meta-analysis: pharmacologic treatment of obesity Ann Intern Med 2005 142 7 532 546 15809465
   PubMed Web of Science ®Google Scholar
• Padwal R Li SK Lau DC Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials Int J Obes Relat Metab Disord 2003 27 12 1437 1446 12975638
   PubMed Web of Science ®Google Scholar
• Sjöström L Rissanen A Andersen T Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group Lancet 1998 352 9123 167 172 9683204
   PubMed Web of Science ®Google Scholar
• McNeely W Benfield P Orlistat Drugs 1998 56 2 241 249 discussion 250 9711448
   PubMed Web of Science ®Google Scholar
• Johansson K Neovius K DeSantis SM Rössner S Neovius M Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis Obes Rev 2009 10 5 564 575 19460116
   PubMed Web of Science ®Google Scholar
• Novo Nordisk Saxenda Product Monograph 2016 Available from: http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Saxenda_PM_English.pdf Accessed April 3, 2017
   Google Scholar
• Astrup A Carraro R Finer N Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide Int J Obes (Lond) 2012 36 6 843 854 21844879
   PubMed Web of Science ®Google Scholar
• Davies MJ Bergenstal R Bode B Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial JAMA 2015 314 7 687 699 26284720
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X Astrup A Fujioka K A randomized, controlled trial of 3.0 mg of liraglutide in weight management N Engl J Med 2015 373 1 11 22 26132939
   PubMed Web of Science ®Google Scholar
• Wadden TA Hollander P Klein S Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study Int J Obes (Lond) 2013 37 11 1443 1451 23812094
   PubMed Web of Science ®Google Scholar
• Woods SC D’Alessio DA Central control of body weight and appetite J Clin Endocrinol Metab 2008 93 11 Suppl 1 S37 S50 18987269
   PubMed Web of Science ®Google Scholar
• Delgado-Aros S Kim DY Burton DD Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans Am J Physiol Gastrointest Liver Physiol 2002 282 3 G424 431 11841992
   PubMed Web of Science ®Google Scholar
• Astrup A Rössner S Van Gaal L Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 2009 375 9701 1606 1616
   Web of Science ®Google Scholar
• Mucklow JC Martindale: the complete drug reference Br J Clin Pharmacol 2000 49 6 613
   Google Scholar
• Apotex Revia Monograph 2003 Available from: http://shoppers-healthcare-portal-a88a1f4b.s3.amazonaws.com/AgilityUGC/bd7cfe4d-a0ae-4496-a4e4-f2ebdbaf6f5d/EN_PM00003584.PDF Accessed June 25, 2017
   Google Scholar
• Ornellas T Chavez B Naltrexone SR/Bupropion SR (Contrave): a new approach to weight loss in obese adults P T 2011 36 5 255 262 21785538
   PubMedGoogle Scholar
• Thomsen WJ Grottick AJ Menzaghi F Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization J Pharmacol Exp Ther 2008 325 2 577 587 18252809
   PubMed Web of Science ®Google Scholar
• Wadden TA Foreyt JP Foster GD Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial Obesity 2011 19 1 110 120 20559296
   PubMed Web of Science ®Google Scholar
• Greenway FL Fujioka K Plodkowski RA Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet 2010 376 9741 595 605 20673995
   PubMed Web of Science ®Google Scholar
• Smith SR Weissman NJ Anderson CM Multicenter, placebo-controlled trial of lorcaserin for weight management N Engl J Med 2010 363 3 245 256 20647200
   PubMed Web of Science ®Google Scholar
• O’Neil PM Smith SR Weissman NJ Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study Obesity (Silver Spring) 2012 20 7 1426 1436 22421927
   PubMed Web of Science ®Google Scholar
• Bleich SN Bennett WL Gudzune KA Cooper LA National survey of US primary care physicians’ perspectives about causes of obesity and solutions to improve care BMJ Open 2012 2 e001871
   Web of Science ®Google Scholar